Intragraft Cytomegalovirus Infection: A Randomized Trial of Valacyclovir Prophylaxis versus Pre-Emptive Therapy in Renal Transplant Recipients
- 1 January 2010
- journal article
- research article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 15 (1), 23-30
- https://doi.org/10.3851/imp1485
Abstract
In a randomized study, we observed a higher incidence of biopsy-proven acute rejection with pre-emptive valganciclovir therapy as compared with valacyclovir prophylaxis for prevention of cytomegalovirus (CMV) disease after renal transplantation (RTx). Persistence of the virus within the allograft could stimulate the alloimmune response. The aim of our study was to evaluate intragraft CMV infection in patients randomized to the trial. RTx recipients at risk of CMV were randomized to pre-emptive therapy with valganciclovir (n=36) for significant CMV viraemia (> or =2,000 copies/ml by quantitative PCR in whole blood samples) or 3-month prophylaxis with valacyclovir (n=34). Renal biopsies performed during 12 months post-RTx were analysed for the presence of CMV by real-time PCR and immunohistochemical staining. A total of 35 patients (59 biopsies) in the pre-emptive group and 31 patients (57 biopsies) with valacyclovir prophylaxis had > or =1 biopsy specimen with sufficient material for intragraft CMV determination. Cumulative incidence of intragraft CMV infection was 14% and 7% (P=0.315) with pre-emptive therapy and prophylaxis, respectively. Patients at risk for primary CMV infection (CMV serological donor-positive and recipient-negative) were at higher risk for intragraft CMV infection (40% versus 5%; P=0.008). CMV viraemia at the time of biopsy was associated with the presence of CMV within the allograft (P<0.001). During the first year after RTx, the incidence of intragraft CMV infection was relatively low with comparable rates in patients managed by pre-emptive valganciclovir therapy and valacyclovir prophylaxis.Keywords
This publication has 33 references indexed in Scilit:
- Cell-Mediated Immunity to Predict Cytomegalovirus Disease in High-Risk Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2009
- High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft functionTransplant Immunology, 2009
- Valacyclovir Prophylaxis Versus Preemptive Valganciclovir Therapy to Prevent Cytomegalovirus Disease After Renal TransplantationAmerican Journal of Transplantation, 2008
- Cytomegalovirus-associated allograft rejection in heart transplant patientsCurrent Opinion in Infectious Diseases, 2007
- Banff ’05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (’CAN’)American Journal of Transplantation, 2007
- Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survivalTransplant International, 2006
- Rat Cytomegalovirus Infection Interferes with Anti-CD4 mAb-(RIB 5/2) Mediated Tolerance and Induces Chronic Allograft DamageAmerican Journal of Transplantation, 2006
- The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients1Transplantation, 2003
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationNew England Journal of Medicine, 1999
- DIRECT INDUCTION OF MHC CLASS I, BUT NOT CLASS II, EXPRESSION ON ENDOTHELIAL CELLS BY CYTOMEGALOVIRUS INFECTIONTransplantation, 1989